| JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan M Kudo, O Matsui, N Izumi, H Iijima, M Kadoya, Y Imai, T Okusaka, ... Liver cancer 3 (3-4), 458-468, 2014 | 632 | 2014 |
| Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update M Kudo, Y Kawamura, K Hasegawa, R Tateishi, K Kariyama, S Shiina, ... Liver cancer 10 (3), 181-223, 2021 | 409 | 2021 |
| Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update M Kudo, O Matsui, N Izumi, M Kadoya, T Okusaka, S Miyayama, ... Oncology 87 (Suppl. 1), 22-31, 2014 | 266 | 2014 |
| Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma A Hiraoka, T Kumada, K Michitaka, H Toyoda, T Tada, H Ueki, M Kaneto, ... Journal of gastroenterology and hepatology 31 (5), 1031-1036, 2016 | 241 | 2016 |
| Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more … A Hiraoka, K Michitaka, T Kumada, N Izumi, M Kadoya, N Kokudo, S Kubo, ... Liver cancer 6 (4), 325-336, 2017 | 236 | 2017 |
| Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis A Hiraoka, T Kumada, K Tsuji, K Takaguchi, E Itobayashi, K Kariyama, ... Liver cancer 8 (2), 121-129, 2019 | 181 | 2019 |
| Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and … A Hiraoka, T Kumada, M Kudo, M Hirooka, K Tsuji, E Itobayashi, ... Liver cancer 6 (3), 204-215, 2017 | 174 | 2017 |
| Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis A Hiraoka, K Michitaka, D Kiguchi, H Izumoto, H Ueki, M Kaneto, ... European journal of gastroenterology & hepatology 29 (12), 1416-1423, 2017 | 147 | 2017 |
| Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study K Ueshima, N Nishida, S Hagiwara, T Aoki, T Minami, H Chishina, ... Cancers 11 (7), 952, 2019 | 137 | 2019 |
| Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis A Hiraoka, T Kumada, M Atsukawa, M Hirooka, K Tsuji, T Ishikawa, ... Cancer Medicine 8 (8), 3719-3728, 2019 | 136 | 2019 |
| Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites T Uehara, M Hirooka, K Ishida, A Hiraoka, T Kumagi, Y Kisaka, Y Hiasa, ... Journal of gastroenterology 42, 306-311, 2007 | 134 | 2007 |
| Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure A Hiraoka, N Horiike, SMF Akbar, K Michitaka, T Matsuyama, M Onji Journal of gastroenterology 40, 52-56, 2005 | 133 | 2005 |
| Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis A Hiraoka, T Kumada, M Kudo, M Hirooka, Y Koizumi, Y Hiasa, K Tajiri, ... Digestive diseases 35 (6), 602-610, 2017 | 128 | 2017 |
| Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of … A Hiraoka, N Horiike, Y Yamashita, Y Koizumi, Y Yamamoto, A Hasebe, ... Hepato-gastroenterology 55 (88), 2171-2174, 2008 | 112 | 2008 |
| Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients A Hiraoka, T Kumada, K Michitaka, M Kudo Liver cancer 8 (5), 312-325, 2019 | 109 | 2019 |
| Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) A Hiraoka, T Kumada, K Kariyama, K Takaguchi, M Atsukawa, ... Clinical features of lenvatinib for unresectable hepatocellular carcinoma in …, 2019 | 107 | 2019 |
| Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation A Hiraoka, T Aibiki, T Okudaira, A Toshimori, T Kawamura, H Nakahara, ... Journal of gastroenterology 50, 1206-1213, 2015 | 103 | 2015 |
| Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: multicenter analysis A Hiraoka, T Kumada, K Kariyama, K Takaguchi, M Atsukawa, ... Cancer medicine 8 (1), 137-146, 2019 | 98 | 2019 |
| Virtual sonographic radiofrequency ablation of hepatocellular carcinoma visualized on CT but not on conventional sonography M Hirooka, H Iuchi, T Kumagi, S Shigematsu, A Hiraoka, T Uehara, ... American journal of roentgenology 186 (5_supplement), S255-S260, 2006 | 93 | 2006 |
| Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib A Hiraoka, M Hirooka, Y Koizumi, H Izumoto, H Ueki, M Kaneto, ... Hepatology Research 47 (6), 558-565, 2017 | 90 | 2017 |
